Pacira BioSciences Inc. (NASDAQ:PCRX) saw an upside of 5.82% to close Monday at $50.76 after adding $2.79 on the day. The 5-day average trading volume is 831,180 shares of the company’s common stock. It has gained $51.45 in the past week. An average of 590,085 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 458,800.
PCRX’s 1-month performance is -8.38% or -$4.64 on its low of $45.05 reached on 10/11/21. The company’s shares have touched a 52-week low of $47.02 and high of $80.00, with the stock’s rally to the 52-week high happening on 02/25/21. YTD, PCRX has lost -15.17% or -$9.08. However, the current price is down -36.55%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Jul 29, 75 days have gone by since the last insider trading activity for Pacira BioSciences Inc. (PCRX). Riker Lauren Bullaro (Vice President, Finance) most recently sold 90 shares at $60.81 per share on Jul 29. This transaction cost the insider $5,473. Vice President, Finance, Riker Lauren Bullaro, sold 2,410 shares at a price of $60.85 on Jul 28. Then, on Jul 02, President, Rest of World REINHARDT MAX sold 421 shares at a price of $59.76 per share. This transaction amounted to $25,159.
The company’s PE ratio for the last five years has touched a high of 1170.75 and a low of 12.27. PCRX stock has a beta of 1.03. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.55 while the price-to-book (PB) in the most recent quarter is 3.26, with the price to cash flow ratio at 27.59.
Pacira BioSciences Inc.’s quick ratio for the period ended June 29 was 3.20, with the current ratio over the same period at 3.50 meaning that PCRX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.47, while the total debt to equity was 0.69. In terms of profitability, the gross margin trailing 12 months is 73.80%. The trailing 12-month EBITDA margin is 16.62% while for the period ending June 29; Pacira BioSciences Inc.’s operating margin was 16.40%. The firm’s gross profit as reported stood at $312.32 million against revenue of $429.65 million.
For the quarterly period ending June 29 this year, Pacira BioSciences Inc.’s cash and short-term investments amounted to $540.82 million against total debt of $549.27 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected PCRX to announce $0.74 per share in earnings in its latest quarter, but it posted $0.77, representing a 4.10% surprise. EBITDA for the quarter stood at more than $46.14 million. PCRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 638.66 million, with total debt at $549.27 million. Shareholders hold equity totaling $44.45 million
Let’s look briefly at Pacira BioSciences Inc. (PCRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 40.20% to suggest the stock is trending Neutral, with historical volatility in this time period at 80.18%.
The stock’s 5-day moving average is $48.90, reflecting a +2.65% or $1.31 change from its current price. PCRX is currently trading -8.61% above its 20-day SMA, -20.82% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -13.89% and -13.50% respectively.
Stochastic %K and %D was 19.46% and 14.39% and the average true range (ATR) pointed at 2.65. The RSI (14) points at 39.39%, while the 14-day stochastic is at 38.53% with the period’s ATR at 2.43. The stock’s 9-day MACD Oscillator is pointing at -2.40 and -4.67 on the 14-day charts.
In the most recent analyst report for Pacira BioSciences Inc. (NASDAQ: PCRX), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for PCRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PCRX as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 10 have offered a “buy” rating.
What is PCRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $54.00 and a high of $93.00, with their median price target at $84.00. Looking at these predictions, the average price target given by analysts is for Pacira BioSciences Inc. (PCRX) stock is $79.77.